Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Tempus AI , Inc. (NASDAQ: TEM) stock rose 3% on Wednesday after the precision medicine technology company announced it received 510(k) clearance from the U.S. Foo ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

Wearables and telehealth are teaming up to transform chronic care. This connected model offers real-time data for proactive, ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...